A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Trial details
- Registry ID
- NCT05271604
- Phase
- Phase 2
The FDA approved Cetuximab (Erbitux) on 12 Feb 2004.
Drug identity checked against registry records
Also recorded as Erbitux
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT05271604 | BioAtla, Inc. | Phase 2 | Completed | 2025-09-22Actual |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsNCT07020221 | VSTM | Phase 1, Phase 2 | Recruiting | 2028-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2004-02-12Day | Cetuximab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125084", "applicant_as_listed_by_fda": "IMCLONE", "brand_names": ["ERBITUX"], "active_ingredients": ["CETUXIMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20040212", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |